Clear Harbor Asset Management LLC Acquires New Position in Bristol Myers Squibb Company $BMY

Clear Harbor Asset Management LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,971 shares of the biopharmaceutical company’s stock, valued at approximately $690,000.

A number of other institutional investors have also bought and sold shares of BMY. Northwestern Mutual Investment Management Company LLC lifted its position in Bristol Myers Squibb by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares in the last quarter. KCM Investment Advisors LLC grew its holdings in Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 174 shares in the last quarter. Sandy Cove Advisors LLC increased its stake in shares of Bristol Myers Squibb by 4.7% in the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 176 shares during the last quarter. Investment Research Partners LLC increased its stake in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 179 shares during the last quarter. Finally, ESG Planning DBA Harper Investing raised its holdings in shares of Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after acquiring an additional 180 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $67.06 on Monday. The stock has a fifty day simple moving average of $60.55 and a 200-day simple moving average of $59.39. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a market cap of $136.98 billion, a PE ratio of 14.77, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the firm earned $1.46 EPS. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Jefferies Financial Group cut shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.